Correvio Pharma Corp. is exploring options including putting itself up for sale, a day after a panel of experts advising the U.S. health regulator voted against approving the company’s heart drug.

U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp.’s Brinavess said they did not believe the benefits of the heart drug outweighed the therapy’s risks, sending the company’s shares down nearly 38 percent.

Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.

A Pennsylvania state court judge overturned a $27.8 million jury award to an Indiana couple who accused Bayer and J&J of failing to warn of internal bleeding risks.

German drugmaker Bayer moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto, requesting approval in Europe to make atherosclerosis patients eligible for treatment.

BridgeBio Pharma, which was founded in 2015, recently closed on a $135 million series C round that was co-led by Viking Global Investors and KKR. They were joined by Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Janus Funds.

A federal jury cleared Bayer and J&J of liability in the third case to go to trial out of thousands of lawsuits claiming their blood thinner Xarelto led to severe internal bleeding.

A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. German and U.S. firms are leading the way in synthetic messenger RNA, or mRNA technology, a new approach to tackling a […]